Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Precision Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,859,245

697 payments

Through program year 2025, Precision Clinical Research is reported as receiving $2,859,245 in research payments, across 697 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $52,741 10
2024 Research $500,674 23
2023 Research $332,522 536
2022 Research $600,988 51
2021 Research $386,034 43
2020 Research $23,000 3
2019 Research $963,286 31

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $988,609 48 payments
  2. Ironwood Pharmaceuticals, Inc $854,702 18 payments
  3. IBSA Institut Biochimique SA $322,110 12 payments
  4. Moderna TX, Inc. $304,636 438 payments
  5. Braintree Laboratories, Inc. $85,707 15 payments
  6. TissueTech, Inc. $61,614 105 payments
  7. Urovant Sciences Inc $57,156 18 payments
  8. Romark Laboratories, LC $48,039 1 payment
  9. E.R. Squibb & Sons, L.L.C. $47,736 6 payments
  10. Acerus Pharmaceuticals Corporation $26,160 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $825,475 29 payments
  2. C3718-302 $796,802 14 payments
  3. A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) $322,110 12 payments
  4. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $222,448 427 payments
  5. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $143,403 12 payments
  6. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $81,187 10 payments
  7. McP-103-312 $57,900 4 payments
  8. A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza $48,039 1 payment
  9. A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease $27,604 3 payments
  10. A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $27,078 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record